Clinical trial
Linagliptin's Effect on CD34+ Stem Cells
NCT02467478
Study timeline
Study start (actual)2015-04-01Date precision: month
Registry last updated2023-01-19
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Type 2 Diabetesunresolved
Impaired Renal Functionunresolved
Interventions
LinagliptinDRUG · verified · RxNorm: linagliptin
PlaceboDRUG
Sponsors & collaborators
George Washington Universitylead sponsor
Boehringer Ingelheimcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02467478 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.